Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial)

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma

(2016) Caroline Happold et al.   JOURNAL OF CLINICAL ONCOLOGY

Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed?

(2016) Michela Buglione et al.   JOURNAL OF NEURO-ONCOLOGY

Minimizing the uncertainties regarding the effects of delaying radiotherapy for Glioblastoma: A systematic review and meta-analysis

(2016) Luiz Victor Maia Loureiro et al.   RADIOTHERAPY AND ONCOLOGY

Delaying standard combined chemoradiotherapy after surgical resection does not impact survival in newly diagnosed glioblastoma patients

(2016) Guillaume Louvel et al.   RADIOTHERAPY AND ONCOLOGY

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma

(2015) Manfred Westphal et al.   EUROPEAN JOURNAL OF CANCER

International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme

(2015) Wilson Roa et al.   JOURNAL OF CLINICAL ONCOLOGY

USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance

(2015) Jin-Ku Lee et al.   NEURO-ONCOLOGY

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2 Trial of Hypofractionated High-Dose Intensity Modulated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

(2014) Toshihiko Iuchi et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: A 6 year single institutional experience

(2013) Patrizia Ciammella et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival

(2013) Christopher A. Barker et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Postoperative treatment of glioblastoma multiforme with radiation therapy plus concomitant and adjuvant temozolomide : A mono-institutional experience of 215 patients

(2013) DayaNand Sharma et al.   Journal of Cancer Research and Therapeutics

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

(2013) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme

(2013) M. Kerkhof et al.   NEURO-ONCOLOGY

Phase II Trial of Hypofractionated IMRT With Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme

(2012) Krishna Reddy et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Simultaneous Integrated Boost Intensity-Modulated Radiotherapy in Patients With High-Grade Gliomas

(2010) Kwan Ho Cho et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide

(2010) Giuseppe Minniti et al.   RADIOTHERAPY AND ONCOLOGY

Intensity-modulated radiation therapy in newly diagnosed glioblastoma: A systematic review on clinical and technical issues

(2010) Dante Amelio et al.   RADIOTHERAPY AND ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Accelerated Hypofractionated Intensity-Modulated Radiotherapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma Multiforme: A Safety and Efficacy Analysis

(2008) Valerie Panet-Raymond et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS